Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $750.00 Price Target at Citigroup

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price dropped by equities research analysts at Citigroup from $795.00 to $750.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Citigroup’s target price would suggest a potential upside of 9.54% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. Evercore ISI decreased their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target for the company. Finally, JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $684.71 on Tuesday. Regeneron Pharmaceuticals has a 1-year low of $666.25 and a 1-year high of $1,211.20. The company’s 50-day moving average is $727.19 and its 200 day moving average is $936.01. The firm has a market capitalization of $75.24 billion, a P/E ratio of 16.94, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Institutional Trading of Regeneron Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $26,000. Fairfield Financial Advisors LTD purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $37,000. Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $49,000. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.